NNVCHealthcare · Biotechnology

NNVC Stock Forecast: NanoViricides, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026

$1.02

0.00% on the day

The 2 Wall Street analysts covering NanoViricides, Inc. hold a median 12-month price target of $6 — +488.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 58 of 100 as at 12 Sept 2026 — in the upper half.

Market cap

$26.0M

Ticker Nerd rank

58 / 100

Median analyst target

$6.00

Analysts covering

Revenue$0.0

Operating income−$2.0M

Net income−$2.0M

Free cash flow−$1.9M

Quarterly, 8 quarters to 31 Mar 2026 · latest quarter's figure shown

Total return, dividends reinvested

−11.3%

−25.0%

YTD

−9.7%

−28.7%

From 52W high

−49.8%

From 52W low

+20.0%

$0.85

$2.03

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

NNVC stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores NanoViricides, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026

58 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Growth

Accruals

Volatility

Value

Momentum

Revisions

Quality

Issuance

Size (87): Smaller than most of the companies we track.

Issuance (33): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

NNVC stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NNVC, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts

2 Buy0 Hold0 Sell

Low $6.00Median $6.00High $6.00

The green dot is the last close — the median target sits +488.2% from it.

Recent analyst actionsNewest first

Date	Firm	Action	Rating	Target
6 July 2026	Noble Capital Markets	Initiates	Outperform	—
7 May 2024	EF Hutton	Reiterates	Buy	—
16 Feb 2024	EF Hutton	Reiterates	Buy	—
1 June 2023	EF Hutton	Assumes	Buy	$5.25
18 Apr 2023	EF Hutton	Reiterates	Buy	—
28 Feb 2023	EF Hutton	Maintains	Buy	$8.50 → $5.25

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NNVC appears on the weeks it earns a place.

Performance

NNVC vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, NanoViricides, Inc. returned −28.7% against +17.5% for the S&P 500, dividends included.

NNVC vs S&P 500, last 12 monthsTotal return, rebased to 100

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

NNVC analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

NanoViricides, Inc. (NNVC) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: −1.6×
Price / sales: —
Price / book: 2.4×
EV / EBITDA: −2.5×

Growth & margins

Revenue growth (YoY): —
Earnings growth (YoY): —
Gross margin: —
Operating margin: 0.0%
Net margin: 0.0%

Returns & dividend

Return on equity: −90.0%
Return on assets: −50.5%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

NanoViricides, Inc. (NNVC) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

NanoViricides, Inc. has a market value of $26.0M and an enterprise value of $18.9M.
Revenue in the twelve months to 31 Mar 2026: $0.0.
Net income over the same four quarters: −$8.1M.
Free cash flow in the twelve months to 31 Mar 2026: −$7.4M, after $95K of capital spending.
Shares outstanding: 21.6M.
Trailing P/E: −1.6×; forward P/E: −2.9× — the forward figure prices analyst consensus estimates, not reported earnings.
NanoViricides, Inc. employs 7 people.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 12 Sept 2026

Data provided by Twelve Data

Peers

NNVC vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology

Company	Market cap	TKN rank
NNVCNanoViricides, Inc.	$26.0M	58
QNTMQuantum BioPharma Ltd.	$25.9M	41
CVMCEL-SCI Corp.	$26.0M	35
ACTUActuate Therapeutics, Inc.	$25.7M	31
PLRZPolyrizon Ltd.	$26.2M	12
ATOSAtossa Therapeutics, Inc.	$25.0M	24
TVRDTvardi Therapeutics, Inc.	$24.9M	29

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own NanoViricides, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest NNVC news & analysis

Clinical Trial for an Oral Drug to Treat Ebola is Registered in the Pan African Clinical Trials Database and is Ready to Go, As the Largest Ebola Outbreak Continues to Expand in DR Congo

Accesswire · 8 Sept 2026positive

NanoViricides announced that its Phase II clinical trial of NV-387 Oral Gummies for treating Bundibugyo Ebolavirus and other Ebola viruses in the Democratic Republic of Congo has been successfully registered in the Pan African Clinical Trials Registry database, receiving identification number PACTR202608748555077.

Why it matters — This registration marks a formal step toward launching the company's oral Ebola treatment trial in the context of an expanding outbreak in the DRC.

While Measles Cases Continue to Increase in The USA and Globally, NanoViricides is Getting Ready for Clinical Trials of Its Revolutionary Broad-spectrum Drug Candidate NV-387 as A Treatment for Measles

Accesswire · 31 Aug 2026positive

NanoViricides provided an update on its Measles Drug Treatment Program as confirmed US measles cases reached 2,903 as of August 27, 2026, exceeding the 2,289 cases recorded in all of 2025. The company is preparing for clinical trials of its broad-spectrum drug candidate NV-387 as a treatment for measles.

Why it matters — NNVC watchers would care because the rising measles case count highlights the potential relevance and progress of NanoViricides' NV-387 candidate as it moves toward clinical trials in this treatment area.

The Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo to Fight the Current Largest Ever and Expanding Ebola Outbreak to Begin Soon

Accesswire · 18 Aug 2026positive

NanoViricides announced that its Phase II clinical trial of NV-387 Oral Gummies as a treatment for the Bundibugyo ebolavirus and other Ebola viruses is expected to begin soon in the Democratic Republic of Congo. Professor Patrick Katoto has been appointed as principal investigator to lead the trial.

Why it matters — This marks progress for NanoViricides' lead antiviral candidate NV-387 moving into a Phase II trial against an active Ebola outbreak, a significant clinical milestone for the company.

NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak

Accesswire · 10 Aug 2026positive

NanoViricides announced that it has received regulatory approval from the DRC's local agency ACOREP to begin a Phase II clinical trial of its NV-387 Oral Gummies as a treatment for Bundibugyo Ebolavirus and other Ebola viruses. The company has retained Om Sai Clinical Research Private Limited as the CRO for this trial in the DRC.

Why it matters — A NNVC watcher would care because this marks regulatory approval to advance NV-387 into a Phase II Ebola trial amid the current outbreak in the DRC.

NanoViricides Awaits Approval from DR Congo Regulatory Agency for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola, Financing Completed to Support the Trial

Accesswire · 28 July 2026positive

NanoViricides has filed an application with the DR Congo regulatory agency ACOREP to begin a Phase II clinical trial of NV-387 Oral Gummies as a treatment for the Bundibugyo Ebolavirus, and says it has raised the necessary financing to support the trial.

Why it matters — A NNVC watcher would care because this marks a key regulatory milestone for the company's lead antiviral candidate NV-387 advancing toward a Phase II trial in an active Ebola outbreak setting.

FAQ

Frequently asked questions about NNVC stock

What is the NNVC stock price forecast for 2026-2027?

The 2 Wall Street analysts covering NanoViricides, Inc. have a median 12-month price target of $6, with estimates ranging from $6 to $6. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is NNVC stock a buy right now?

Of the 2 analysts covering NanoViricides, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks NanoViricides, Inc. 58 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank NNVC?

As at 12 Sept 2026, NanoViricides, Inc. ranks 58 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (87 of 100).

Will NNVC stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +488.2% from the last close, and Ticker Nerd's factor model ranks NanoViricides, Inc. 58 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the NNVC stock forecast for 2030?

No analyst covering NanoViricides, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NNVC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $6 over the next 12 months.

How has NNVC stock performed over the past year?

NanoViricides, Inc. returned -28.7% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does NanoViricides, Inc. do?

NanoViricides, Inc. is a clinical-stage biopharmaceutical company focused on developing antiviral therapies using its proprietary nanoviricide platform.

What is the latest news on NNVC?

The most recent item we track (Accesswire, 8 Sept 2026): "Clinical Trial for an Oral Drug to Treat Ebola is Registered in the Pan African Clinical Trials Database and is Ready to Go, As the Largest Ebola Outbreak Continues to Expand in DR Congo". NanoViricides announced that its Phase II clinical trial of NV-387 Oral Gummies for treating Bundibugyo Ebolavirus and other Ebola viruses in the Democratic Republic of Congo has been successfully registered in the Pan African Clinical Trials Registry database, receiving identification number PACTR202608748555077.

Company

About NanoViricides, Inc.

NanoViricides, Inc. is a clinical-stage biopharmaceutical company focused on developing antiviral therapies using its proprietary nanoviricide platform. The company’s current work centers on creating broad-spectrum nanomedicine drugs designed to target and neutralize virus particles before they infect healthy cells. Its lead candidate, NV-387, is being developed for multiple viral infections, including respiratory viruses and other high-priority infectious diseases. NanoViricides also maintains additional antiviral programs addressing conditions such as herpes and other viral threats. The company combines drug discovery, development, and commercialization capabilities within a single business model, supporting its efforts across research, preclinical work, and clinical development. Headquartered in Shelton, Connecticut, NanoViricides occupies a niche position in the healthcare market as a developer of specialized antiviral treatments aimed at complex viral diseases.

CEO Dr. Anil R. Diwan Ph.D. · 7 employees · United States · https://www.nanoviricides.com